Oragenics Inc. (OGEN)

0.4455 0 (0%)

IEX Real-Time Price

August 16, 2018 EST.

NYSE American : Healthcare

Prev Close 0.4455

Price Open 0.5005

Volume: 1,772

Avg Volume: 592,253

Market Cap: 5.27M

P/E Ratio -2.23

52 Wk Range 0.44-6.8



OGEN Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2017-12-29
39.37M
286,908
0.90
0.73%

2017-12-15
39.37M
112,379
0.54
0.29%

2017-11-30
39.37M
37,987
0.33
0.10%

2017-11-15
39.37M
91,415
1.98
0.23%




OGEN Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-07-02
Q1 2018
N/A
0.00 (0)
0.00
0.00

2017-11-13
Q3 2017
N/A
0.00 (0)
0.00
0.00

2017-08-14
Q2 2017
N/A
0.00 (0)
-0.02
0.00

2017-05-15
Q1 2017
N/A
0.00 (0)
-0.04
0.00

News

Oragenics, Inc. Resumes Phase 2 Clinical Trial of AG013 in Oral Mucositis Following Positive Routine Safety Review (2018-08-15 07:30 Business Wire)

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it has resumed its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential treatment …

 


Statistics

Shares Outstanding: 11.84M

Top 15 Institution Percent: 45.30

Price To Sales: N/A

Price To Book: 1180.81

Revenue: N/A

Gross Profit: N/A

Cash: 11.18M

Debt: 4.95M

Return On Assets: -162.04

Return On Equity: 653.55

Profit Margin: N/A

Price History

Beta: 1.07

50-day Moving Avg: 1.01

200-day Moving Avg: 1.93

YTD Change: -80.29

5-day Change: -11.59

1-month Change: -40.60

3-month Change: -63.18

6-month Change: -77.15

1-year Change: -86.70

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Oragenics Inc.

Exchange: NYSE American

Industry: Biotechnology

Sector: Healthcare

Website: http://www.oragenics.com

Oragenics Inc is a biopharmaceutical company which engages in the discovery, development and commercialization of technologies associated with oral health, broad spectrum antibiotics and other general health benefits.